myTomorrows
 | This article needs more citations. (January 2019) |
 | |
| Type | Naamloze Vennootschap |
|---|---|
| Industry | Healthcare, Pharmaceuticals |
| Founded | 2012[1] |
| Headquarters | , |
Key people | Ronald Brus (CEO), Ronald Plasterk (CSO) |
| Products | Experimental drugs |
| Website | mytomorrows.com |
myTomorrows is the trade name of Impatients N.V., a globally active healthcare company.[2] The company is based in the Zuidas, Amsterdam, Netherlands. myTomorrows provides patients with unmet medical needs, and their doctors, information about treatment options worldwide and facilitates access to medicines in development.[3][4] Access to these medicines can be achieved via clinical trials, expanded access and off-label use.
myTomorrows was founded in 2012 by Ronald Brus, former CEO of the biotechnology company Crucell.[1] In the beginning of its existence, myTomorrows has been characterized as innovative and controversial.[5] In May 2013, MP Lea Bouwmeester asked parliamentary question about the company.[5] In December 2017, former minister Ronald Plasterk joined the company as Chief Scientific Officer.[6]
References
[edit]- 1 2 "Dutch life science startup offers access to late-stage drugs for patients with few options". MedCity News. 2014-02-20. Retrieved 20 November 2018.
- ↑ "MyTomorrows, dernière chance pour des patients". Le Monde. Retrieved 21 November 2018.
- ↑ "myTomorrows raises further 10M to help access drugs in development". TechCrunch. Retrieved 20 November 2018.
- ↑ "Patients' Right To Try Should Not Be A License To Fleece Them". Forbes. Retrieved 8 January 2019.
- 1 2 "myTomorrows is de Uber van de medicijnen". NRC Handelsblad. Retrieved 21 November 2018.
- ↑ "Plasterk gaat naar farmabedrijf Mytomorrows". NU.nl. Retrieved 21 November 2018.
External links
[edit]
 | This Dutch corporation or company article is a stub. You can help Wikipedia by adding missing information. |